Get the Stockscreener App
3.245
0.15%
-0.005
Incannex Healthcare Inc stock is traded at $3.245, with a volume of 45,616.
It is down -0.15% in the last 24 hours and up +9.26% over the past month.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
See More
Previous Close:
$3.25
Open:
$3.22
24h Volume:
45,616
Relative Volume:
0.23
Market Cap:
$38.82M
Revenue:
$12,000
Net Income/Loss:
$-48.41M
P/E Ratio:
-0.1889
EPS:
-17.181
Net Cash Flow:
$-19.99M
1W Performance:
-10.85%
1M Performance:
+9.26%
6M Performance:
-18.06%
1Y Performance:
-81.35%
1-Day Range:
$3.22
$3.31
1-Week Range:
$3.1295
$3.615
52-Week Range:
$2.49
$20.31
Incannex Healthcare Inc Stock (IXHL) Company Profile
Name
Incannex Healthcare Inc
Sector
Phone
61 409 840 786
Address
8 CENTURY CIRCUIT, NORWEST NSW
Compare IXHL vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IXHL
Incannex Healthcare Inc
|
3.245 | 43.31M | 12,000 | -48.41M | -19.99M | -17.18 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Incannex Healthcare Inc Stock (IXHL) Latest News
IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms - Stocktwits
Incannex Healthcare (ASX:IHL) Cash Flow Check: What Investors Need to Watch on 19 August - Kalkine Media
Why Is Incannex Healthcare (ASX:IHL) in Market Focus? - Kalkine Media
Why Did IXHL Stock Tank Over 32% Today? - Stocktwits
Incannex Wins US Patent Lift For Sleep Apnoea Pipeline (ASX:IHL) - Kalkine Media
Incannex Healthcare (IXHL) Climbs 3.8% to $3.28, Testing Key Resistance ZoneMcClellan Summation - vinanet.vn
Polar Asset Management (IXHL) reports 7.0% beneficial stake via 900,000 warrants - Stock Titan
$Incannex Healthcare (IXHL.US)$ - Moomoo
Incannex (ASX:IHL): What Is Changing in the Liquidity Test? - Kalkine Media
Why Does Incannex Healthcare (ASX:IHL) Shape Discipline? - Kalkine Media
Incannex Healthcare (ASX:IHL) Clinical Development Pipeline: Market Outlook - Kalkine Media
Incannex Healthcare Inc. (IXHL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incannex Healthcare Inc. (IXHL) options chain - Yahoo Finance Singapore
Why Are Incannex Healthcare (ASX:IHL), Cann Group (ASX:CAN), ECS Botanics (ASX:ECS) and Little Green Pharma (ASX:LGP) Back in the Market Spotlight? - Kalkine Media
Why Are BrainChip (ASX:BRN), Incannex Healthcare (ASX:IHL), Lake Resources (ASX:LKE) and Cann Group (ASX:CAN) Back in the Market Spotlight? - Kalkine Media
Incannex receives final A$5.1m R&D tax incentive refund By Investing.com - Investing.com UK
Incannex Healthcare Inc. (IXHL) stock price, news, quote and history - Yahoo Finance Singapore
Incannex receives final A$5.1m R&D tax incentive refund - Investing.com
Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026 - The Manila Times
Form 8K Incannex Healthcare Inc. For: 11 August By Investing.com - Investing.com Nigeria
Press Release: Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026 - Moomoo
Incannex receives A$5.1M final R&D refund, totaling A$11.2M non-dilutive funding - TradingView
Can Incannex (ASX:IHL) Reshape The Cannabis Conversation? - Kalkine Media
Incannex Healthcare Inc (IXHL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Incannex Healthcare Inc. (IXHL) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Incannex Healthcare Inc (IXHL) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Incannex Healthcare Inc. Revenue Breakdown – NASDAQ:IXHL - TradingView
IXHL|Incannex Healthcare Inc|Price:2.985|Chg%:+0.035 - TradingKey
Incannex Healthcare Inc (IXHL) Institutional Confidence - TradingKey
Incannex Healthcare Inc (IXHL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Incannex Healthcare Inc (IXHL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Incannex Healthcare Inc (IXHL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Incannex Healthcare Inc. Commences Participant Screening In Dreamzz Phase 2 Study Of IHL-42X For Obstructive Sleep Apnea - marketscreener.com
Incannex starts screening for Phase 2 study of IHL-42X to treat obstructive sleep apnea with FDA Fast Track status - Pluang
Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea - The Manila Times
Incannex Commences Screening in Phase 2 DReAMzz Study of IHL-42X for OSA - TradingView
What Has Incannex (ASX:IHL) in Health Debate? - Kalkine Media
Incannex Healthcare (IXHL) Slides Toward Support as Selling Pressure IntensifiesHigh Yield Stocks - vinanet.vn
IXHL Q2 2026 Earnings: Massive EPS Miss Highlights Cash Burn as Clinical-Stage Biotech Reports No Revenue - vinanet.vn
IXHL Q2 2026 Earnings: Significant EPS Miss Amid Operational ExpendituresGuidance vs Actual - vinanet.vn
IXHL Q2 2026 Earnings: Substantial EPS Miss Reflects Near-Term ChallengesProfit Margin Analysis - vinanet.vn
Incannex Healthcare (IXHL) Edges Higher: Technical Levels in Focus After Modest GainMarket Leader Picks - vinanet.vn
Incannex Healthcare Secures US Patent Grant for Obstructive Sleep Apnea Treatment IHL-42XFinancial Health Score - Vinanet
Incannex Secures US Patent for Sleep Apnea Drug Candidate IHL-42X - Sleep Review
Incannex (IXHL) Secures U.S. Patent Grant in Obstructive Sleep Apnea for IHL-42X - Yahoo Finance
Incannex Healthcare Inc Stock (IXHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.66%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):